Literature DB >> 18768780

Identification and characterization of novel small-molecule protease-activated receptor 2 agonists.

Luis R Gardell1, Jian-Nong Ma, Jimmi Gerner Seitzberg, Anne E Knapp, Hans H Schiffer, Ali Tabatabaei, Christopher N Davis, Michelle Owens, Bryan Clemons, Kenneth K Wong, Birgitte Lund, Norman R Nash, Yan Gao, Jelveh Lameh, Kara Schmelzer, Roger Olsson, Ethan S Burstein.   

Abstract

We report the first small-molecule protease-activated receptor (PAR) 2 agonists, AC-55541 [N-[[1-(3-bromo-phenyl)-eth-(E)-ylidene-hydrazinocarbonyl]-(4-oxo-3,4-dihydro-phthalazin-1-yl)-methyl]-benzamide] and AC-264613 [2-oxo-4-phenylpyrrolidine-3-carboxylic acid [1-(3-bromo-phenyl)-(E/Z)-ethylidene]-hydrazide], each representing a distinct chemical series. AC-55541 and AC-264613 each activated PAR2 signaling in cellular proliferation assays, phosphatidylinositol hydrolysis assays, and Ca(2+) mobilization assays, with potencies ranging from 200 to 1000 nM for AC-55541 and 30 to 100 nM for AC-264613. In comparison, the PAR2-activating peptide 2-furoyl-LIGRLO-NH(2) had similar potency, whereas SLIGRL-NH(2) was 30 to 300 times less potent. Neither AC-55541 nor AC-264613 had activity at any of the other PAR receptor subtypes, nor did they have any significant affinity for over 30 other molecular targets involved in nociception. Visualization of EYFP-tagged PAR2 receptors showed that each compound stimulated internalization of PAR2 receptors. AC-55541 and AC-264613 were well absorbed when administered intraperitoneally to rats, each reaching micromolar peak plasma concentrations. AC-55541 and AC-264613 were each stable to metabolism by liver microsomes and maintained sustained exposure in rats, with elimination half-lives of 6.1 and 2.5 h, respectively. Intrapaw administration of AC-55541 or AC-264613 elicited robust and persistent thermal hyperalgesia and edema. Coadministration of either a tachykinin 1 (neurokinin 1) receptor antagonist or a transient receptor potential vanilloid (TRPV) 1 antagonist completely blocked these effects. Systemic administration of either AC-55541 or AC-264613 produced a similar degree of hyperalgesia as was observed when the compounds were administered locally. These compounds represent novel small-molecule PAR2 agonists that will be useful in probing the physiological functions of PAR2 receptors.

Entities:  

Mesh:

Substances:

Year:  2008        PMID: 18768780     DOI: 10.1124/jpet.108.142570

Source DB:  PubMed          Journal:  J Pharmacol Exp Ther        ISSN: 0022-3565            Impact factor:   4.030


  19 in total

Review 1.  Targeting proteinase-activated receptors: therapeutic potential and challenges.

Authors:  Rithwik Ramachandran; Farshid Noorbakhsh; Kathryn Defea; Morley D Hollenberg
Journal:  Nat Rev Drug Discov       Date:  2012-01-03       Impact factor: 84.694

Review 2.  Protease-activated receptor 2 signaling in inflammation.

Authors:  Andrea S Rothmeier; Wolfram Ruf
Journal:  Semin Immunopathol       Date:  2011-10-06       Impact factor: 9.623

3.  pH-evoked dural afferent signaling is mediated by ASIC3 and is sensitized by mast cell mediators.

Authors:  Jin Yan; Xiaomei Wei; Christina Bischoff; Rebecca M Edelmayer; Gregory Dussor
Journal:  Headache       Date:  2013-06-28       Impact factor: 5.887

4.  Discovery of Novel Nonpeptidic PAR2 Ligands.

Authors:  Ilona Klösel; Maximilian F Schmidt; Jonas Kaindl; Harald Hübner; Dorothee Weikert; Peter Gmeiner
Journal:  ACS Med Chem Lett       Date:  2020-05-22       Impact factor: 4.345

5.  Itch: Cells, Molecules, and Circuits.

Authors:  Kush N Patel; Xinzhong Dong
Journal:  ACS Chem Neurosci       Date:  2011-01-19       Impact factor: 4.418

6.  II. In vitro evidence that (-)-OSU6162 and (+)-OSU6162 produce their behavioral effects through 5-HT2A serotonin and D2 dopamine receptors.

Authors:  Ethan S Burstein; Maria L Carlsson; Michelle Owens; Jian-Nong Ma; Hans H Schiffer; Arvid Carlsson; Uli Hacksell
Journal:  J Neural Transm (Vienna)       Date:  2011-08-25       Impact factor: 3.575

7.  Development of highly potent protease-activated receptor 2 agonists via synthetic lipid tethering.

Authors:  Andrea N Flynn; Justin Hoffman; Dipti V Tillu; Cara L Sherwood; Zhenyu Zhang; Renata Patek; Marina N K Asiedu; Josef Vagner; Theodore J Price; Scott Boitano
Journal:  FASEB J       Date:  2013-01-04       Impact factor: 5.191

8.  A brief exposure to tryptase or thrombin potentiates fibrocyte differentiation in the presence of serum or serum amyloid p.

Authors:  Michael J V White; Elkin Galvis-Carvajal; Richard H Gomer
Journal:  J Immunol       Date:  2014-11-26       Impact factor: 5.422

9.  Potent agonists of the protease activated receptor 2 (PAR2).

Authors:  Scott Boitano; Andrea N Flynn; Stephanie M Schulz; Justin Hoffman; Theodore J Price; Josef Vagner
Journal:  J Med Chem       Date:  2011-02-04       Impact factor: 7.446

Review 10.  Protease-activated receptors and prostaglandins in inflammatory lung disease.

Authors:  Terence Peters; Peter J Henry
Journal:  Br J Pharmacol       Date:  2009-10       Impact factor: 8.739

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.